Loading clinical trials...
Loading clinical trials...
A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Recurrent, Metastatic or Persistent Cervical Carcinoma
Conditions
Interventions
LN-145
LN-145 + pembrolizumab
Locations
43
United States
St. Joseph's Hospital and Medical Center Center For Women's Health
Phoenix, Arizona, United States
University of Southern California
Los Angeles, California, United States
University of California San Diego
San Diego, California, United States
Sylvester Comprehensive Cancer Center
Miami, Florida, United States
University of Florida Health Cancer Center
Orlando, Florida, United States
University of South Florida H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
Start Date
June 22, 2017
Primary Completion Date
August 22, 2025
Completion Date
August 22, 2025
Last Updated
September 17, 2025
NCT06157151
NCT05969860
NCT06349642
NCT05639972
NCT06319963
NCT07343531
Lead Sponsor
Iovance Biotherapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions